This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): T62
Description: Oral T-62 is thought to enhance the effect of endogenous adenosine in the spinal cord and thus provides pain relief by the same mechanism as intrathecally administered adenosine.
Deal Structure: In October 2010, Pfizer and King Pharmaceuticals announced that they have entered into a definitive merger agreement. In February 2011, Pfizer completed its acquisition of King.
Additional information available to subscribers only: